Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AJ Complement inhibitors
L04AJ01 Eculizumab
D03940 Eculizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Complement Inhibitors
Eculizumab
D03940 Eculizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
63 Biological preparations
639 Miscellaneous
6399 Others
D03940 Eculizumab (USAN/INN); Eculizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Organismal systems
Complement and coagulation
C5
D03940 Eculizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03940
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03940
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03940
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03940
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D03940
